Jeffrey Aronin is a successful businessman who lives in the greater Chicago area. He is the chairman of the board and chief executive officer of Paragon Biosciences, LLC. He has been with this firm since January 2010. This company is in the healthcare industry. He founded a company in this industry in August 2000 which was Ovation Pharmaceuticals.
Paragon Biosciences is a startup incubator and is also an investment firm which focuses on companies the biotechnology industry. The goal is to help people live lives that are longer as well as healthier. Jeffrey Aronin says that the companies they invest in are those that are seeking to cure debilitating diseases. The leadership team he put together at Paragon Biosciences are responsible for helping to secure FDA approval for 13 drugs.
Jeffrey Aronin is also the chairman and CEO for this firm’s sister company, Paragon Pharmaceutical Capital. This company is another investment company which invests globally in life science firms. Jeff Aronin established these companies and then manage them as well. Additionally, he has a seat on the board of directors of Discover Financial Services. He started this position back in June 2007.
At Paragon Biosciences, Jeffrey Aronin says they invest in companies which are developing really important medicines that treat a wide variety of diseases. They use their expertise to help the biotech companies make scientific breakthroughs faster by helping them streamline their processes and work much more efficiently. They also gain access to capital from Paragon BioSciences (http://weeklyopinion.com/2018/03/jeff-aronin-improves-lives/). Jeffrey Aronin says that scientific discovery takes the latest technology matched with professionals who are dedicated to scientific rigor.
In 2009, Jeffrey Aronin was the president and CEO of another firm in the healthcare industry, Lundbeck Inc. Paragon Biosciences has partnered with several firms in order to develop new medicines. Jeffrey Aronin says that some of these partners are Debra, Fidelity Investments, Valor Equity Partners, Diaderm, and Twi B.